Zobrazeno 1 - 10
of 237
pro vyhledávání: ''
Autor:
Zihan Xu, Yujie Zhao, Yong Zhang, Xiaowei Liu, Linlin Song, Meixu Chen, Guixiu Xiao, Xuelei Ma, Hubing Shi
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundAlthough prognostic models based on pyroptosis-related genes (PRGs) have been constructed in bladder cancer (BLCA), the comprehensive impact of these genes on tumor microenvironment (TME) and immunotherapeutic response has yet to be investi
Externí odkaz:
https://doaj.org/article/94ad5b2e96f4474a85b600e2622d2143
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Hepatocellular carcinoma (HCC) is one of the cancers that seriously threaten human health. Immunotherapy serves as the mainstay of treatment for HCC patients by targeting the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L
Externí odkaz:
https://doaj.org/article/85f0bdd94d9a4b56a1ca3acfc2e4c3a3
Autor:
Yizhou Wang, Peipei Shang, Chang Xu, Wei Dong, Xiaofeng Zhang, Yong Xia, Chengjun Sui, Cheng Yang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer. However, pathogenetic mechanisms, molecular determinants of recurrence, and predictive biomarkers for first-line treatment (anti
Externí odkaz:
https://doaj.org/article/f83637fb38594066b884975911724056
Autor:
Lele Ye, Xinya Tong, Kan Pan, Xinyu Shi, Binbing Xu, Xuyang Yao, Linpei Zhuo, Su Fang, Sangsang Tang, Zhuofeng Jiang, Xiangyang Xue, Weiguo Lu, Gangqiang Guo
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundSerous ovarian carcinoma (SOC) is considered the most lethal gynecological malignancy. The current lack of reliable prognostic biomarkers for SOC reduces the efficacy of predictive, preventive, and personalized medicine (PPPM/3PM) in patien
Externí odkaz:
https://doaj.org/article/37fbb6c0ce474e2eaa0c14d5e3b121d9
Autor:
Bing Lu, Jiawen Shi, Tong Cheng, Congshuo Wang, Manyu Xu, Pingping Sun, Xiaojing Zhang, Lei Yang, Peng Li, Han Wu, Xiaoling Kuai
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveGastric cancer (GC) is the world’s third-leading cause of cancer-related mortality; the prognosis for GC patients remains poor in terms of a lack of reliable biomarkers for early diagnosis and immune therapy response prediction. Here, we a
Externí odkaz:
https://doaj.org/article/a21dc17e8013423f9dc81f3736aae8ba
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: IL4I1, also known as Interleukin-4-induced gene 1, is an enzyme that can modulate the immune system by acting as a L-amino acid oxidase. Nevertheless, a precise understanding of the correlation of IL4I1 with immunological features and i
Externí odkaz:
https://doaj.org/article/18f2cfb070ff48b0b12edecac562fc2e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe role of RNA-binding fox one homolog 2 (RBFOX2) in the progression of multiple tumors is increasingly supported by evidence. However, the unclearness pertaining to the expression of RBFOX2, its prognostic potential, and its correlation w
Externí odkaz:
https://doaj.org/article/4bacefadacbc4648a2b06e18ecef714a
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease with a prevalence of 150–250 cases per million individuals. Autoantibodies include long-lived antibodies against the acetylcholine receptor (AChR), mainly of the IgG1 subclass, and I
Externí odkaz:
https://doaj.org/article/700d19aaa45047cf815591f296773871
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/33b28907ccca40119143ecb71c8cc63c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundDespite extensive literature on therapeutic strategies for cervical cancer, a bibliometric analysis specifically focused on immunotherapy for advanced, recurrent, or metastatic (A/R/M) cervical malignancies remains unexplored. This study ai
Externí odkaz:
https://doaj.org/article/d6db6795004040d7bcffd37231dd1e3a